✦ LIBER ✦

Hematopoietic stem cell gene therapy for Niemann–Pick disease and other lysosomal storage diseases

✍ Scribed by Edward H Schuchman

Book ID: 108313468
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 249 KB
Volume: 102
Category: Article
ISSN: 0009-3084
DOI: 10.1016/s0009-3084(99)00086-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gene therapy/cell therapy for lysosomal

Gene therapy/cell therapy for lysosomal storage disease

✍ Y. Eto; T. Ohashi 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 64 KB

Gene therapy for lysosomal storage disea

Gene therapy for lysosomal storage diseases: the lessons and promise of animal models

✍ N. Matthew Ellinwood; Charles H. Vite; Mark E. Haskins 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 596 KB

## Abstract There are more than 40 different forms of inherited lysosomal storage diseases (LSDs) known to occur in humans and the aggregate incidence has been estimated to approach 1 in 7000 live births. Most LSDs are associated with high morbidity and mortality and represent a significant burden

Hematopoietic stem cell gene therapy lea

Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease

✍ Miranda, S R P; Erlich, S; Friedrich, V L; Gatt, S; Schuchman, E H 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 571 KB

Hepatic veno-occlusive disease after hem

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies

✍ Ho, V T; Revta, C; Richardson, P G 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 186 KB

Evidence for both endogenous and exogeno

Evidence for both endogenous and exogenous sources of the sphingomyelin storage in lymphoid cell lines from patients with Niemann-Pick disease types A and B

✍ T. Levade; R. Salvayre; A. Maret; L. Douste-Blazy 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 620 KB

Partial phenotypic correction and immune

Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of α-glucosidase in Pompe disease

✍ Gaëlle Douillard-Guilloux; Emmanuel Richard; Lionel Batista; Catherine Caillaud 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB 👁 1 views

## Abstract ## Background Glycogen storage disease type II (GSDII) or Pompe disease is an inherited disease of glycogen metabolism caused by a lack of functional lysosomal acid α‐glucosidase (GAA). Affected individuals store glycogen in lysosomes resulting in fatal hypertrophic cardiomyopathy and